Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belvarafenib in solid tumors
NCT02405065Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Belvarafenib in solid tumor, sponsored by Hanmi Pharmaceutical. Primary endpoint: Safety and tolerability at Day 28. Started Jan 2015; status: completed.
02
Drugs
Belvarafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02405065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405065.